Therefore, in addition to the previously reported associations of low TREX1 expression and increased DNA methylation of TREX1 promoter with increased tumor sensitivity to chemotherapy and radiation therapy [47–49, 51, 52], mutations and copy number changes of TREX1 are likely to play additional contributing roles in tumor response to treatment. This evidence concerns the gene TREX1 and neoplasm.